IP Library Granted Patent US 10,308,966
Granted Patent B2
US 10,308,966 · App. 16/195,480 · Granted Jun 4, 2019

Nucleic acids encoding engineered imine reductases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,308,966
App. No.
16/195,480
Granted
Jun 4, 2019
Kind
B2
Abstract

The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

Claims (26)

1. An engineered polynucleotide encoding an engineered polypeptide having imine reductase activity, wherein said polypeptide has at least 90% sequence identity to the polypeptide SEQ ID NO:2, and comprises a substitution at a position corresponding to position 293 of SEQ ID NO:2, wherein the amino acid at position 293 has been replaced with an aromatic, non-polar, aliphatic, basic, or polar residue.

2. The engineered polynucleotide encoding the engineered polypeptide having imine reductase activity of claim 1 , wherein said polypeptide has at least 90% sequence identity to the polypeptide of SEQ ID NO:2, wherein the amino acid at the position corresponding to position 293 of SEQ ID NO:2 has been replaced with leucine.

3. The engineered polynucleotide encoding the engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1a) pyruvate,

and substrate compound (2b) butylamine

to product compound (3b), N-2-(butylamino)propanoic acid,

under suitable reaction conditions.

4. The engineered polynucleotide encoding the engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1b) cyclohexanone,

and substrate compound (2a) L-norvaline

to product compound (3c), (S)-2-(cyclohexylamino)pentanoic acid,

under suitable reaction conditions.

5. The engineered polynucleotide encoding the engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1b) cyclohexanone,

and substrate compound (2b) butylamine

to product compound (3d), N-butylcyclohexanamine,

under suitable reaction conditions.

6. The engineered polynucleotide encoding the engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1i),

and substrate compound (2b)

to product compound (3n),

under suitable reaction conditions.

7. The engineered polynucleotide encoding the engineered polypeptide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1j),

and substrate compound (2b)

to product compound (3o),

under suitable reaction conditions.

8. A vector comprising the engineered polynucleotide of claim 1 .

9. The vector of claim 8 , further comprising at least one control sequence.

10. A host cell comprising the vector of claim 8 .

11. A host cell comprising the vector of claim 9 .

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Cited By (1)
US 12,421,532